
Opinion|Videos|January 12, 2024
Strategies for Managing Treatment-Naïve CLL with High-Risk Features
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Advertisement
Episodes in this series

Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


